LMR Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

LMR Partners’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,627	Closed	-$792K	–	1516
2022 Q1	$792K	Sell	9,627 -8,500	-47%	-$869K	0.01%	891
2021 Q4	$2.66M	Buy	18,127 +16,101	+795%	+$2.5M	0.03%	396
2021 Q3	$358K	Sell	2,026 -8,884	-81%	-$1.43M	﹤0.01%	855
2021 Q2	$1.76M	Buy	+10,910	New	+$1.75M	0.03%	399
2017 Q3	–	Sell	-64,760	Closed	-$236K	–	588
2017 Q2	$236K	Buy	+64,760	New	+$248K	0.01%	505

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

LMR Partners's MRTX Position: Q2 2022 in Review

LMR Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 9,627 shares — an estimated $792K sold.

LMR Partners first reported a position in MRTX in Q2 2017 and held it in 5 quarters. The position peaked at $2.66M in Q4 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

LMR Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
LMR Partners sold 9,627 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $792K.
LMR Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 5 quarters.
LMR Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $2.66M in Q4 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on LMR Partners's 13F filing for Q2 2022, filed 15 Aug 2022.